trending Market Intelligence /marketintelligence/en/news-insights/trending/JBSj0kQmLgVoFp71spgBFg2 content esgSubNav
In This List

Eisai, Purdue Pharma seek US FDA approval for sleep disorder treatment

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Eisai, Purdue Pharma seek US FDA approval for sleep disorder treatment

Eisai Co. Ltd. and Purdue Pharma LP are seeking U.S. Food and Drug Administration approval for lemborexant as a treatment for insomnia, a sleep disorder.

The new drug application submitted to the regulator was based on the results of two phase 3 trials called Sunrise 1 and Sunrise 2, which enrolled about 2,000 patients.

Lemborexant works by acting the orexin neurotransmitter system, which regulates a person's wakefulness.

Tokyo's Eisai and Stamford, Conn.-based privately held company Purdue Pharma are jointly developing the therapy for sleep-wake disorders. Lemborexant is also slated for a phase 2 study in patients with irregular sleep-wake rhythm disorder and mild to moderate Alzheimer's dementia.